Enadenotucirev

Enadenotucirev
Virus classification
(unranked):	Virus
Realm:	Varidnaviria
Kingdom:	Bamfordvirae
Phylum:	Preplasmiviricota
Class:	Pharingeaviricetes
Order:	Rowavirales
Family:	Adenoviridae
Genus:	Mastadenovirus
Species:	Human mastadenovirus B

Enadenotucirev is an investigational oncolytic virus that is in clinical trials for various cancers.

It is an oncolytic A11/Ad3 Chimeric Group B Adenovirus, previously described as ColoAd1.

Enadenotucirev has also been modified with additional genes using the tumor-specific immuno-gene therapy (T-SIGn) platform to develop novel cancer gene therapy agents.^{[citation needed]}

The T-SIGn vectors at clinical study stage are:^{[citation needed]}

• NG-350A: This vector contains two transgenes expressing the heavy and light chains for a secreted CD40 agonist monoclonal antibody.
• NG-641: This vector contains four transgenes expressing secreted interferon alpha, the chemokines CXCL9, CXCL10 and an anti-FAP/anti-CD3 bispecific T-cell activator

In Jan 2015 the European Medicines Agency's (EMA) Committee for Orphan Medical Products (COMP) designated enadenotucirev as an orphan medicinal product for the treatment of ovarian cancer.

Clinical trials

Two clinical trials have been completed with enadenotucirev. The EVOLVE study and the MOA study.

As of June 2019^[update], there are two active phase 1 trials: OCTAVE (in ovarian cancer) and SPICE (in multiple solid tumor indications).

Of the T-SIGn viruses, NG-350A has an ongoing clinical study.

See also

• Oncolytic adenovirus
  • Oncolytic adenovirus § Directed evolution

References

This oncology article is a stub. You can help Wikipedia by adding missing information.

• v
• t
• e